- TransCode Therapeutics Inc RNAZ has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138.
- TTX-MC138 is TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors.
- The award totals $2.3 million expected over three years.
- TransCode expects to file IND in Q1 of 2022. TransCode's proprietary TTX platform leverages an iron oxide nanoparticle as a novel, image-guided system to safely and efficiently deliver oligonucleotides to their intended RNA target. TTX-MC138 targets MicoRNA-10b believed to drive metastatic disease.
- Price Action: RNAZ shares are up 4.27% at $3.41 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
